乔治临床( George Clinical ) welcomes The Taiwan Food and Drug Administration’s (TFDA) recent clarified timelines for approval of a general Clinical Trial Authority (CTA) at 45 calendar days. […]
了解更多The importance of securing strong, long-standing investigator networks with leading research hospitals and clinics is critical to the continued growth of the clinical trial environment in coun […]
了解更多乔治临床( George Clinical ), a leading clinical research organization (CRO) in the Asia-Pacific region, has gained recognition of the organization’s strong support of the Mandatory Provident Fund […]
了解更多乔治临床( George Clinical ) welcomes the decision by the FDA to approve the delivery of CAR-T therapy in a partnership between Methodist Healthcare, and 乔治临床( George Clinical ) Scientific Leader, […]
了解更多Beijing, November 13, 2018 – 乔治临床( George Clinical ), a leading clinical research organization (CRO) in the Asia-Pacific region, has continued its involvement and collaboration with the Heart […]
了解更多9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window […]
了解更多
In another encouraging step towards making China a leading destination for clinical drug trials, some critical developments were announced at The Executive Meeting of the State Council on the […]
了解更多
George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. 乔治临床 […]
了解更多
Significant changes are ahead for clinical research in China. The Public Consultation Notice for Policies to Encourage Innovation and Reform in Regulation of Drug and Medical Device Clinical T […]
了解更多
Sydney, Australia (May 2, 2017) – 乔治临床( George Clinical ), a leading full-service CRO in the Asia-Pacific region and Vector Oncology, a Memphis-based leader in oncology research and data analy […]
了解更多
